3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
134
Carcinoma, Non-Small-Cell Lung
133
Prostatic Neoplasms
87
Lung Neoplasms
43
Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
30
Neoplasm Metastasis
29
Stomach Neoplasms
26
Head and Neck Neoplasms
24
Esophageal Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
17
Pancreatic Neoplasms
17
Ovarian Neoplasms
16
Urinary Bladder Neoplasms
13
Sarcoma
12
Adenocarcinoma of Lung
9
Triple Negative Breast Neoplasms
8
Fallopian Tube Neoplasms
8
Carcinoma, Transitional Cell
8
Carcinoma, Ovarian Epithelial
8
Adenocarcinoma Of Esophagus
7
Recurrence
6
Inflammatory Breast Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma
5
Breast Neoplasms, Male
5
Adenocarcinoma, Bronchiolo-Alveolar
5
Laryngeal Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Advanced Solid Tumors
4
Interventions
sitravatinib
1
Nivolumab
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Metastatic Non-Squamous Non-Small Cell Lung Cancer
×
Docetaxel
×
Clear all
NCT03906071
2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3
Completed
577 enrolled
22 charts